Biogaia Ab Class B · OMXSTO:BIOG_B
Biogaia Ab Class B — Q3 2026 Earnings Presentation
20 slides from Biogaia Ab Class B's earnings presentation, Oct 22, 2026
Slide 1: Q3 2026 Results
Q3 2026 RESULTS Telephone Conference 22 October 2026 Theresa Agnew, CEO Alexander Kotsinas, CFO
Slide 2: Financial Highlights Q3 2026
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Financial Highlights Q3 2026 GROWTH EXCLUDING NET SALES EBIT CURRENCY EFFECTS MARGIN 23% 400 MSEK 33% 2
Slide 3: Executive Summary Q3 2026
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Executive Summary Q3 2026 • Net sales reached 400.4 MSEK (326.6), with growth excluding currency effects of 23% (23% including currency effects) • Sales in EMEA increased b
Slide 4: BioGaia Strategy
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks BioGaia Strategy Expansion through Grow Direct Markets the Core Gut Health / Colic Oral Health Immune Health Breakthrough Innovation Foundations People & Culture Invest for
Slide 5: Delivering on Our Strategy
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Delivering on Our Strategy • Strong growth across both Pediatrics and Adult Health segments, supported by Protectis® Drops, Protectis® Tablets and Prodentis® Grow the Core
Slide 6: Launches
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Launches Distributor Country Product Abbott Turkey Protectis easydropper 5 ml BioGaia UK UK & Ireland Protectis strawberry kids tablets with vitamin D BioGaia UK UK & Irela
Slide 7: Key Events
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Key Events • 31 August: BioGaia signed a new long-term exclusive distribution agreement with Recordati for Spain and Portugal • 9 September: Launch of BioGaia® Colus®, a pr
Slide 8: Growth Excluding FX by Business Segment Q3
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Growth Excluding FX by Business Segment Q3 Total Pediatrics Adult Health +23% +21% +29% 73% share of revenue 26% share of revenue Sales of BioGaia Protectis drops increased
Slide 9: Sales per Segment
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Sales per Segment Sales per Segment Q3 2026 MSEK Q3 Q3 Change Total YTD YTD Change Total 1% 2026 2025 excl FX change 2026 2025 excl FX change 26% Pediatrics 293 243 21% 21%
Slide 10: Sales per Region
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Sales per Region Sales per Region Q3 2026 MSEK Q3 Q3 Change Total YTD YTD Change Total 2026 2025 excl FX change 2026 2025 excl FX change 45% 31% EMEA 123 91 38% 35% 430 351
Slide 11: Financials
Alexander Kotsinas, CFO Financials 11
Slide 12: Key Financials
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Key Financials Sales (MSEK) Gross profit (MSEK) EBIT (MSEK) +20% +23% 292 400 243 +54% 327 133 86 74% 73% 26% 33% Q3 2025 Q3 2026 Q3 2025 Q3 2026 Q3 2025 Q3 2026 12
Slide 13: Sales Bridge
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Sales Bridge +23% 75 -1 327 400 Q3 2025 Growth excluding Currency Q3 2026 currency effects effect Change 23% 0% 13
Slide 14: Gross Margin per Segment
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Gross Margin per Segment Gross margin Q3 2026 Q3 2025 YTD 2026 YTD 2025 Pediatrics 74% 76% 75% 75% Adult Health 69% 69% 66% 67% Total 73% 74% 72% 73% • Total: The gross mar
Slide 15: Operating Expenses (OPEX)
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Operating Expenses (OPEX) MSEK Q3 2026 Q3 2025 Change YTD 2026 YTD 2025 Change Sales and Marketing -136 -116 17% -422 -367 15% Research and Development -26 -26 0% -80 -79 1
Slide 16: Profit and Loss Statement
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Profit and Loss Statement MSEK Q3 2026 Q3 2025 Change YTD 2026 YTD 2025 Change Sales 400 327 23% 1,214 1,098 11% Gross profit 292 243 20% 880 805 9% Percentage of revenue 7
Slide 17: Cash Flow
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Cash Flow YTD YTD MSEK Q3 2026 Q3 2025 Change Change 2026 2025 Cash flow from operating activities 106 69 +37 270 241 +30 before changes in net working capital Changes in w
Slide 18: Concluding Remarks
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Concluding Remarks • Strong Q3 performance with 23% growth excluding currency effects and an EBIT margin of 33% • Double-digit growth across both segments, with Pediatrics
Slide 19: Q&A
Q&A
Slide 20: BioGaia
BioGaia.